New Phase Overview
New Phase, is at the forefront of breakthrough solutions in Oncology. New Phase’s Nanotechnology System is a novel solution designed to treat metastatic solid tumors through delivery of thermal energy to malignant cells, thereby causing cancer cell death via electromagnetic hyperthermia, without harming healthy tissues and without side effects. Promising early feasibility studies show either tumor destruction or stable disease in patients that are already exhausted all other treatments. New Phase technology can act as a stand-alone treatment, which aims to prolong the patient's life, with a chronic treatment which turn the disease to be manageable. This solution can be offered to stage IV patients either tried everything or would like an alternative approach instead of curable attempts which contain severe side effects The technology involves two primary components developed by New Phase: Sarah Nanoparticles (SaNPs) and an Electromagnetic Induction System (EIS). The SaNPs are proprietary biocompatible nanoparticles containing multi core of super paramagnetic iron oxide. They are administered intravenously to the patient and localized via the Enhanced Permeability and Retention (EPR) effect on cancer cells. Following delivery and accumulation of the particles on malignant tissue, the patient undergoes regional body alternating magnetic field (AMF) application with the EIS at ~290 kHz. The SaNPs are activated by absorbing the AMF energy, converting it to thermal energy and reaching the desired temperature of 50°C. Cancer cells cannot survive at 50°C while healthy cells remain unharmed. As a result, this process leads to the destruction of malignant cells without causing damage to healthy cells.
Cumulative Funding Raised Over Time ($)
$35.0MDec 2023
Latest News
growth-positive
By heating tumors at the cellular level, New Phase hopes to transform treatment outcomes.
New Phase, an Israeli startup, is developing a novel cancer treatment using nanoparticles to heat tumors selectively, aiming to transform metastatic cancer into a manageable chronic condition. Their technology, currently in Phase I clinical trials, has shown promising early results without toxicities. The U.S. FDA has classified their technology as a medical device, potentially shortening its path to market. Despite the global cancer treatment markets growth, New Phase faces challenges in securing domestic funding due to a lack of expertise in deep-science startups among Israeli venture capital firms. To date, the company has raised $35 million, primarily from foreign investors, and aims to extend patients lives significantly.
Product StageInvestmentFDA approved/pending approval
growth-positive
פריצות הדרך הישראליות שישנו את המאבק בסרטן - ניו פייז
Biolojic Design is developing AI-designed smart antibodies for targeted cancer treatment, currently in phase two clinical trials in the US and Australia. Unlike traditional drugs, these antibodies specifically target cancer cells, minimizing damage to healthy cells. Initial results show tumor reduction in patients with melanoma, lung, kidney, and bladder cancers. The companys innovative approach involves programming antibodies as biological software for specific targets. Biolojics team, comprising biologists, immunologists, and computer scientists, is expanding the platforms application to other diseases. This development represents a significant advancement in oncology, leveraging AI technology to enhance precision in cancer therapy.
Product StageFDA approved/pending approval
growth-positive
חום, ברזל וחוצפה ישראלית: הנשק הסודי של "ניו פייז" נגד הסרטן הגרורתי
In the midst of Israels war challenges, the Israeli biotechnology company New Phase continues its crucial fight against metastatic cancer. Despite four of its employees being called up for military reserve duty, the company has made significant progress in developing groundbreaking technology. Boaz Shalev, the companys engineering manager, recently returned from 87 days of reserve duty and shared how Israeli resilience and technological innovation are merging on the scientific front against one of humanitys toughest diseases. The company, which employs 23 people, has developed an innovative electromagnetic hyperthermia technology using iron-based nanoparticles to treat stage 4 metastatic cancer. Currently, they are conducting a Phase I clinical trial at Beilinson Hospital, treating over 15 patients with encouraging results.
CustomersInvestment
growth-positive
Groundbreaking Israeli cancer treatment gets FDA approval for clinical trials in U.S. | CTech
Israeli company New Phase has received FDA approval to begin clinical trials in the U.S. for its groundbreaking cancer treatment solution. The treatment, which has shown success in Phase 1 clinical trials, uses New Phase’s patented Sarah Nanotechnology System to distinguish between healthy and cancerous cells, ensuring that only cancerous cells are targeted and destroyed. The company has so far successfully treated 20 patients with lung, colon, cervical and liver cancer. They plan to begin a clinical trial at a U.S. hospital by the end of the summer, with the goal of completing the trial by the end of 2026.
InvestmentExpand
growth-positive
"פרוע וחסר מעצורים": היזם שרוצה להפוך את הסרטן למחלה כרונית
NewPhase, a company co-founded by Ofer Shalev and Raphi Hof, has been developing a technology based on heating cancer cells for their destruction. After two years of meeting with about 200 investors, they received negative responses. However, a decade later, the company is in the first stage of human trials and the signs are encouraging. The companys goal is not to eradicate the disease, but to give a few more good years to terminal patients.
Investment
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $35M |
| Last funding | Undisclosed |
| Stage | A |
| Rounds | 3 |
| Investors | 0 |
Team Members
12
Employees: 11-50
Web & Social Links
| Website | newphase.co.il/ |
Locations
Odem Street 5, Petah Tikva, Israel
Photos & Videos
1 item(s)
New Phase Business
Business models
B2B
Product stage
Clinical Trial
Employees
11-50
Sector
Health Tech & Life SciencesMedical DevicesMedical Treatment & TherapeuticsTarget Customer
Healthcare & Life SciencesHealthcareProvidersLife SciencesPharmaceuticalsMedical Devices IndustryCore Technology
SensingBiologicalsCellsTags (7)
therapeuticsnanotechnologycellsmedical-devicesbiotechnologycell-therapycancer-therapyGeographic Markets
IsraelNorth AmericaNew Phase Financials
$35M
Total funding
Undisclosed
Capital raised
Undisclosed
Last funding
A
Funding stage
3
Total rounds
0
Investors
Cumulative Funding Raised Over Time ($)
$35.0MDec 2023
Private Equity Funding
A Round
Dec 2023
$35M
Non-Equity Funding
GrantEvent
Jan 2024
Undisclosed
GrantEvent
Jan 2023
Undisclosed
BIRD Foundation
New Phase Lifecycle
Cumulative Funding Raised Over Time
$35.0MDec 2023
All Events
A Round
Dec 2023
$35M
GrantEvent
Jan 2024
Undisclosed
GrantEvent
Jan 2023
Undisclosed
BIRD Foundation
New Phase News
10 articles
growth-positive
By heating tumors at the cellular level, New Phase hopes to transform treatment outcomes.
New Phase, an Israeli startup, is developing a novel cancer treatment using nanoparticles to heat tumors selectively, aiming to transform metastatic cancer into a manageable chronic condition. Their technology, currently in Phase I clinical trials, has shown promising early results without toxicities. The U.S. FDA has classified their technology as a medical device, potentially shortening its path to market. Despite the global cancer treatment markets growth, New Phase faces challenges in securing domestic funding due to a lack of expertise in deep-science startups among Israeli venture capital firms. To date, the company has raised $35 million, primarily from foreign investors, and aims to extend patients lives significantly.
Product StageInvestmentFDA approved/pending approval
growth-positive
פריצות הדרך הישראליות שישנו את המאבק בסרטן - ניו פייז
Biolojic Design is developing AI-designed smart antibodies for targeted cancer treatment, currently in phase two clinical trials in the US and Australia. Unlike traditional drugs, these antibodies specifically target cancer cells, minimizing damage to healthy cells. Initial results show tumor reduction in patients with melanoma, lung, kidney, and bladder cancers. The companys innovative approach involves programming antibodies as biological software for specific targets. Biolojics team, comprising biologists, immunologists, and computer scientists, is expanding the platforms application to other diseases. This development represents a significant advancement in oncology, leveraging AI technology to enhance precision in cancer therapy.
Product StageFDA approved/pending approval
growth-positive
חום, ברזל וחוצפה ישראלית: הנשק הסודי של "ניו פייז" נגד הסרטן הגרורתי
In the midst of Israels war challenges, the Israeli biotechnology company New Phase continues its crucial fight against metastatic cancer. Despite four of its employees being called up for military reserve duty, the company has made significant progress in developing groundbreaking technology. Boaz Shalev, the companys engineering manager, recently returned from 87 days of reserve duty and shared how Israeli resilience and technological innovation are merging on the scientific front against one of humanitys toughest diseases. The company, which employs 23 people, has developed an innovative electromagnetic hyperthermia technology using iron-based nanoparticles to treat stage 4 metastatic cancer. Currently, they are conducting a Phase I clinical trial at Beilinson Hospital, treating over 15 patients with encouraging results.
CustomersInvestment
growth-positive
Groundbreaking Israeli cancer treatment gets FDA approval for clinical trials in U.S. | CTech
Israeli company New Phase has received FDA approval to begin clinical trials in the U.S. for its groundbreaking cancer treatment solution. The treatment, which has shown success in Phase 1 clinical trials, uses New Phase’s patented Sarah Nanotechnology System to distinguish between healthy and cancerous cells, ensuring that only cancerous cells are targeted and destroyed. The company has so far successfully treated 20 patients with lung, colon, cervical and liver cancer. They plan to begin a clinical trial at a U.S. hospital by the end of the summer, with the goal of completing the trial by the end of 2026.
InvestmentExpand
growth-positive
"פרוע וחסר מעצורים": היזם שרוצה להפוך את הסרטן למחלה כרונית
NewPhase, a company co-founded by Ofer Shalev and Raphi Hof, has been developing a technology based on heating cancer cells for their destruction. After two years of meeting with about 200 investors, they received negative responses. However, a decade later, the company is in the first stage of human trials and the signs are encouraging. The companys goal is not to eradicate the disease, but to give a few more good years to terminal patients.
Investment
Growth-Positive
ניו-פייז: הכירו את הסטרט אפ שהחליט לנצח את הסרטן - וואלה! כסף
New Phase, an Israeli biotech company, is working on a technology that aims to turn cancer from a fatal disease into a chronic one. The company was founded by Dr. Raphi Hof and Ofer Shalev after Hofs mother was diagnosed with lung cancer. The technology, named Sarah Nano Particles, works by injecting nano particles into the patients body which then reach the cancerous growth. The patient is then placed in a machine developed by the company that generates a non-invasive electromagnetic field, heating the injected particles and thereby destroying the cancer cells without harming normal cells. The company has raised $30 million since its inception.
Investment
growth-positive
קרינה מגנטית נגד סרטן - הסטארט-אפ הישראלי שמפתח טיפול חדשני למחלה | כלכליסט
Israeli startup, ניו פייז, has developed an innovative treatment for cancer using electromagnetic radiation. The treatment slows down the progression of the disease and helps reduce existing tumors. It minimizes severe side effects for patients. The company aims to provide treatment for patients in advanced stages of cancer. The article features an interview with the founder and CEO, Ofer Shalev.
Customers
growth-positive
ניו פייז החלה ניסויים בבני אדם להארכת חיים לחולי...
Medical technology company New Phase has begun human trials of a technology that could extend the lives of terminal cancer patients. The technology, called SANP (Sarah Nano Particles), works by heating cancer cells to a temperature of 50 degrees, killing them without harming healthy cells. The company has completed safety tests in preclinical research and is now testing the effects of the technology in increasing doses. The trial is taking place at the Galilee Medical Center in Nahariya, Israel. New Phase has raised $25 million from Brazilian investors so far and plans to raise an additional $15 million soon.
InvestmentExpand
growth-positive
Former Hadassah chief joins tumor treatment startup
Former Hadassah Hospital CEO Zeev Rotstein has joined the board of directors and scientific advisory council of Israeli solid tumor treatment startup New Phase. The company has raised $25 million to date from investors including Aharon Lukach and RLI Fund. Rotstein will assist in promoting clinical research and planning clinical trials for the companys novel solution for treating metastatic solid tumors. He has also been appointed president and head of the advisory committee of cannabis company EPM.
PartnersInvestment
growth-positive
NewPhase Successfully Completed Small Mammal Pre-clinical Trials of a Cancer Treatment That Transforms Cancer to a Treatable Chronic Ailment
Israeli start-up company NewPhase is developing a treatment for cancer using their patented Sarah nano-particle (SaNP). The treatment utilizes the characteristics of cancer cells to selectively destroy them while sparing normal cells. NewPhase has completed pre-clinical trials and plans to begin Phase I FDA human trials in Q1 2017. The treatment has the potential to significantly improve cancer treatment outcomes and reduce side effects compared to conventional approaches.
CustomersPartners
New Phase Team
Rafael Hof
Co-founder & Board Member
Founder
Arnoldo Cyjon
Chief Medical Officer
Employee Info
| Employees (range) | 11-50 |
| Exact count | 25 |
| Team members | 12 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 12 classification IDs that could be used for matching.
New Phase Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 90/100 |
| Missing | markets, not claimed |
| BI Verification | Yotam Maman |
| Registrar ID | 514957620 |
| Phone | +97236798687 |
| Creator | Yanina Wainscheinker |
| Creator email | yanina.wain@gmail.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2024-11-18T00:00:00.000Z |
| Created | 2021-11-16T00:00:00.000Z |
| Claimed | Yes |